Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups.
| Title: | Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups. |
|---|---|
| Authors: | Doane MJ; Alkermes, Inc., Waltham, MA, USA. michael.doane@alkermes.com.; Raymond K; QualityMetric, Inc. LLC, Johnston, RI, USA.; Saucier C; QualityMetric, Inc. LLC, Johnston, RI, USA.; Bessonova L; Alkermes, Inc., Waltham, MA, USA.; O'Sullivan AK; Alkermes, Inc., Waltham, MA, USA.; White MK; QualityMetric, Inc. LLC, Johnston, RI, USA.; Foster AM; QualityMetric, Inc. LLC, Johnston, RI, USA.; LaGasse K; QualityMetric, Inc. LLC, Johnston, RI, USA.; Carpenter-Conlin J; Alkermes, Inc., Waltham, MA, USA.; Sajatovic M; University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Velligan DI; The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. |
| Source: | BMC psychiatry [BMC Psychiatry] 2023 Apr 12; Vol. 23 (1), pp. 245. Date of Electronic Publication: 2023 Apr 12. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central, [2001- |
| MeSH Terms: | Schizophrenia*/diagnosis ; Bipolar Disorder*/drug therapy ; Bipolar Disorder*/diagnosis ; Antipsychotic Agents*; Humans ; Male ; Female ; Quality of Life ; Focus Groups |
| Abstract: | Background: Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health disorders often treated with antipsychotic medications. This qualitative study sought to better understand disease burden and treatment experiences with oral antipsychotic medications in participants living with SZ or BD-I.; Methods: Six 90-min focus groups were conducted with participants diagnosed with SZ or BD-I. Trained moderators facilitated discussions using a semistructured guide. Participants described symptoms, impacts of disease, and experiences with oral antipsychotic medications, whether favourable or unfavourable.; Results: Among participants with SZ (n = 15; 3 groups, 5 per group), 53% were male and 33% were white, with a mean of 18.6 years since diagnosis. Of participants with BD-I (n = 24; 3 groups, 8 per group), 33% were male and 42% were white, with a mean of 13.0 years since diagnosis. Participants described numerous symptoms of their illnesses that impacted relationships and daily life, including effects on emotional health, the ability to work, and encounters with law enforcement. Previous antipsychotic medications were deemed effective by 14/15 (93%) participants with SZ and 12/16 (75%) participants with BD-I. Most participants with SZ (13/15; 87%) or with BD-I (16/24; 67%) reported discontinuing their antipsychotic medication at some point. Side effects were a common reason for discontinuing or switching medications for participants with SZ (8/15; 53%) and for those with BD-I (11/24; 46%). The most common side effects reported in both cohorts were weight gain, drowsiness, sexual problems, and neurologic symptoms. Side effects negatively affected quality of life, leading to serious health problems and issues with self-esteem.; Conclusions: People living with SZ or BD-I cited a range of favourable and unfavourable experiences with oral antipsychotic medications. Most participants reported that their antipsychotics were effective at controlling their symptoms, but multiple side effects impacted their quality of life, caused additional serious health problems, and often led to discontinuation of or switching antipsychotics. Findings from this study contribute to a better understanding of patients' experiences with antipsychotics and highlight a need for new medications with favourable benefit/risk profiles.; (© 2023. The Author(s).) |
| References: | J Psychopharmacol. 2015 Apr;29(4):353-62. (PMID: 25516373); N Engl J Med. 2005 Sep 22;353(12):1209-23. (PMID: 16172203); BMC Psychiatry. 2020 Jul 6;20(1):354. (PMID: 32631362); BMJ. 1995 Jul 29;311(7000):299-302. (PMID: 7633241); Lancet. 2008 Mar 29;371(9618):1085-97. (PMID: 18374841); Lancet Psychiatry. 2022 Feb;9(2):137-150. (PMID: 35026139); Pharmacotherapy. 2015 Sep;35(9):813-22. (PMID: 26406773); Postgrad Med. 2020 Jan;132(1):80-90. (PMID: 31813311); Nurs Health Sci. 2013 Sep;15(3):398-405. (PMID: 23480423); Psychiatr Serv. 2002 Oct;53(10):1319-21. (PMID: 12364685); Clinicoecon Outcomes Res. 2020 Sep 07;12:481-497. (PMID: 32982338); Eur Psychiatry. 2005 Aug;20(5-6):395-402. (PMID: 16171654); Patient Prefer Adherence. 2020 Oct 28;14:2043-2054. (PMID: 33149559); Drugs. 2004;64(20):2291-314. (PMID: 15456328); BMC Psychiatry. 2021 May 11;21(1):249. (PMID: 33975574); Curr Med Res Opin. 2021 Jan;37(1):109-121. (PMID: 33095689); Bipolar Disord. 2018 Mar;20(2):97-170. (PMID: 29536616); JAMA Psychiatry. 2013 Sep;70(9):931-9. (PMID: 23863861); Int J Soc Psychiatry. 2016 Feb;62(1):12-20. (PMID: 25987581); J Med Econ. 2019 Jan;22(1):63-70. (PMID: 30376745); Bipolar Disord. 2012 Feb;14(1):6-18. (PMID: 22329468); Am J Psychiatry. 2009 Feb;166(2):152-63. (PMID: 19015230); J Clin Psychiatry. 2004 Sep;65(9):1211-8. (PMID: 15367047); Qual Health Res. 2006 Apr;16(4):547-59. (PMID: 16513996); Lancet. 2016 Apr 9;387(10027):1561-1572. (PMID: 26388529); Lancet. 2012 Jun 2;379(9831):2063-71. (PMID: 22560607); J Clin Psychiatry. 2008 Jan;69(1):47-53. (PMID: 18312037); JAMA Psychiatry. 2015 Apr;72(4):334-41. (PMID: 25671328); Qual Health Res. 2019 Aug;29(10):1483-1496. (PMID: 30628545); Psychiatry Res. 2011 Nov 30;190(1):110-4. (PMID: 21571375); Am J Psychiatry. 2013 Mar;170(3):324-33. (PMID: 23318474); J Clin Psychiatry. 2016 Jun;77(6):764-71. (PMID: 27135986); Pharmacoeconomics. 2010;28(7):555-66. (PMID: 20405969); BMC Psychiatry. 2022 Feb 14;22(1):114. (PMID: 35164737) |
| Contributed Indexing: | Keywords: Antipsychotics; Drug side effects; Focus groups; Patient involvement; Patient preference |
| Substance Nomenclature: | 0 (Antipsychotic Agents) |
| Entry Date(s): | Date Created: 20230412 Date Completed: 20230414 Latest Revision: 20230415 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10091535 |
| DOI: | 10.1186/s12888-023-04746-4 |
| PMID: | 37046256 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't